Basic information of RGCC :
| Official Symbol of Gene | RGCC |
| Species | Homo sapiens |
| Entrez Gene ID | 28984 |
| Official Full Name | regulator of cell cycle |
| Also known as | RGC32; RGC-32; C13orf15; bA157L14.2 |
| Gene Type | protein coding |
| dbXrefs | Ensembl:ENSG00000102760 MIM:610077; AllianceGenome:HGNC:20369 |
| Map Location | 13q14.11 |
Sample information of multiple sclerosis:
| Detected Sample | Peripheral blood |
| Sample Detail | N/A |
| Detected Method | Real-time quantitative PCR |
| Disease | MS |
| Disease subtype | RRMS |
| Population | N/A |
| Sample Size | 15 patients with RRMS |
Literature information of multiple sclerosis :
| Pubmed ID | 26407760 |
| Year | 2019 |
| Title | RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis |
Results of multiple sclerosis :
| Expression | up-regulation |
| Risk type | Disease risk |
| Result | Target gene mRNA expression was measured in patients’ isolated PBMCs by real-time qRT-PCR. Compared to stable MS patients, those with acute relapses exhibited decreased expression of RGC-32 (p<0.0001) and FasL (p<0.0001), increased expression of IL-21 (p=0.04), but no change in CDC2 or AKT. Compared to non-responders, responders to GA treatment showed increased expression of RGC-32 (p<0.0001) and FasL (p<0.0001), and decreased expression of IL-21 (p=0.02). Receiver operating characteristic (ROC) analysis was used to assess the predictive accuracy of each putative biomarker. The probability of accurately detecting relapse was 90% for RGC-32, 88% for FasL, and 75% for IL-21. The probability of accurately detecting response to GA was 85% for RGC-32, 90% for FasL, and 85% for IL-21. Our data suggest that RGC-32, FasL, and IL-21 could serve as potential biomarkers for the detection of MS relapse and response to GA therapy. |
| Mechanism/Pathway | We have identified RGC-32, a novel gene product induced by complement activation, and have demonstrated its activity primarily as a cell cycle regulator |
